Cost of digitising the NHS £21bn over the next five years
The cost of digitising the NHS is around £21bn over the next five years, according to new research.
A report from the Health Foundation has analysed the cost needed to put in the infrastructure for digital patient records, cloud storage, cyber security and Wi-Fi, as well as the cost of the skills and capabilities to use it effectively.
Debates around digitising the NHS often centre on the hardware and infrastructure, but the Health Foundation has highlighted the ongoing costs, including software subscriptions and maintenance.
A report in January found some NHS trusts still rely on fax machines, while others "are often still too reliant on paper records".
The Health Foundation said "significant investment" will need to be made in the next five years, including £8bn in capital spending, £3bn in one-off spending and £2bn in annual costs.
Several attempts to digitise the health service have been made - and subsequently abandoned - over the years due to spiralling costs.
A plan to create the world's largest single civilian computer system, linking all parts of the NHS was launched in 2002 and dismantled just over a decade later - despite already costing more than £10bn.
The doomed National Programme for IT had been in disarray for several years before the plug was finally pulled.
The programme had originally been budgeted at around £6bn.
'Reform or die'
The prime minister has previously said the NHS must "reform or die" in the wake of a damning report from Lord Darzi into the state of the health service.
The report - ordered by Health Secretary Wes Streeting days after he took on the role - concluded the health service was in "critical condition" with record waiting lists, and the health of the nation significantly deteriorating in the last 15 years.
Keir Starmer has previously promised to move from an "analogue to a digital NHS" however, a recent report from the Public Accounts Committee has warned "the switch to digital in parts of the NHS has been glacially slow".
2:35
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South Wales Argus
31 minutes ago
- South Wales Argus
Alzheimer's blood test ‘can accurately pick up early symptoms'
Experts from the Mayo Clinic in the US have provided further evidence that blood tests can work to accurately diagnose dementia, by examining two proteins in blood plasma. These proteins – amyloid beta 42/40 and p-tau217 – are associated with amyloid plaque build-up, which is a hallmark of Alzheimer's disease. Researchers found the blood test was highly accurate, with 95% sensitivity, which means it was 95% accurate in picking up people with memory problems, with very few cases missed. It was also 82% for specificity, which means it was also highly accurate in ruling out people without dementia. The study was carried out on more than 500 people in an outpatient memory clinic, meaning it is real-world data. The blood test has already been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the Alzheimer's and Dementia journal, said the test was as good as more invasive tests currently in use. 'Our study found that blood testing affirmed the diagnosis of Alzheimer's disease with 95% sensitivity and 82% specificity,' he said. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Dr Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who show no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. He added: 'This study shows how blood tests are making diagnosis of Alzheimer's disease quicker, easier and more accessible than ever before in a real-world setting. 'While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline – though more research in diverse groups of individuals and in community-based setting is still needed. 'Currently diagnosis options in the UK are often slow, expensive and can be invasive, meaning thousands miss out on the benefits one can bring. 'It's great to see blood tests like this approved for clinical use in the US – we hope to see the same in the NHS, which is why we're part of the Blood Biomarker Challenge.' The Blood Biomarker Challenge is a multi-million-pound research programme supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research. Its goal is to bring blood tests for dementia diagnosis to the NHS by 2029. Dr Oakley said: 'Blood tests will be critical to accelerate diagnosis and give more people access to the care, support and treatments they desperately need faster than ever before. 'We must see long-term investment in the tools and workforce needed to ensure everyone living with dementia can get an early an accurate diagnosis, which is even more important with disease-modifying treatments on the horizon.' Dr Julia Dudley, head of research at Alzheimer's Research UK, said: 'We urgently need to improve how we diagnose dementia and it's great to see international research working towards this goal. 'Blood tests in this study look at p-tau217 and amyloid beta 42/40, and showed the tests offered high accuracy in confirming Alzheimer's disease. 'This study adds to the growing evidence that blood tests can detect the diseases that cause dementia in people with early memory and thinking problems. 'An important point to consider is that people taking part in research don't always reflect the full diversity of those affected by dementia, who might have additional conditions or other characteristics. 'That is why work is needed to understand whether these blood tests work in a real-world setting. 'In the UK, studies like the Blood Biomarker Challenge are helping to build this evidence. 'The study is testing blood tests, including p-tau217, in thousands of people from sites across the UK. 'This work will be a crucial part of making diagnosis easier and faster, which will bring us closer to a cure.'
Rhyl Journal
32 minutes ago
- Rhyl Journal
Alzheimer's blood test ‘can accurately pick up early symptoms'
Experts from the Mayo Clinic in the US have provided further evidence that blood tests can work to accurately diagnose dementia, by examining two proteins in blood plasma. These proteins – amyloid beta 42/40 and p-tau217 – are associated with amyloid plaque build-up, which is a hallmark of Alzheimer's disease. Researchers found the blood test was highly accurate, with 95% sensitivity, which means it was 95% accurate in picking up people with memory problems, with very few cases missed. It was also 82% for specificity, which means it was also highly accurate in ruling out people without dementia. The study was carried out on more than 500 people in an outpatient memory clinic, meaning it is real-world data. The blood test has already been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the Alzheimer's and Dementia journal, said the test was as good as more invasive tests currently in use. 'Our study found that blood testing affirmed the diagnosis of Alzheimer's disease with 95% sensitivity and 82% specificity,' he said. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Dr Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who show no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. He added: 'This study shows how blood tests are making diagnosis of Alzheimer's disease quicker, easier and more accessible than ever before in a real-world setting. 'While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline – though more research in diverse groups of individuals and in community-based setting is still needed. 'Currently diagnosis options in the UK are often slow, expensive and can be invasive, meaning thousands miss out on the benefits one can bring. 'It's great to see blood tests like this approved for clinical use in the US – we hope to see the same in the NHS, which is why we're part of the Blood Biomarker Challenge.' The Blood Biomarker Challenge is a multi-million-pound research programme supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research. Its goal is to bring blood tests for dementia diagnosis to the NHS by 2029. Dr Oakley said: 'Blood tests will be critical to accelerate diagnosis and give more people access to the care, support and treatments they desperately need faster than ever before. 'We must see long-term investment in the tools and workforce needed to ensure everyone living with dementia can get an early an accurate diagnosis, which is even more important with disease-modifying treatments on the horizon.' Dr Julia Dudley, head of research at Alzheimer's Research UK, said: 'We urgently need to improve how we diagnose dementia and it's great to see international research working towards this goal. 'Blood tests in this study look at p-tau217 and amyloid beta 42/40, and showed the tests offered high accuracy in confirming Alzheimer's disease. 'This study adds to the growing evidence that blood tests can detect the diseases that cause dementia in people with early memory and thinking problems. 'An important point to consider is that people taking part in research don't always reflect the full diversity of those affected by dementia, who might have additional conditions or other characteristics. 'That is why work is needed to understand whether these blood tests work in a real-world setting. 'In the UK, studies like the Blood Biomarker Challenge are helping to build this evidence. 'The study is testing blood tests, including p-tau217, in thousands of people from sites across the UK. 'This work will be a crucial part of making diagnosis easier and faster, which will bring us closer to a cure.'
Telegraph
36 minutes ago
- Telegraph
The NHS truths the Left don't want you to hear
Until very recently, Health Secretary Wes Streeting tried to market himself as a radical health reformer, who is not afraid to poke sacred cows. While his reform-minded rhetoric always remained at a highly-abstract and general level, Streeting deserved some credit for it, because he did not have to do this. He had the courage to say things which he knew would rub some people up the wrong way, not least the Corbynite wing of his own party. Sadly, that brief period of NHS candour is now officially over. Streeting, the self-styled reformer, is no more. He and his colleagues have fully retreated into their comfort zone. During the recent local election campaign, Labour distributed a leaflet that showed a mock medical bill, and a doctor holding up a credit card reader. The message was clear: vote for us, because this is what the other lot want to do to you. On Twitter/X, Labour are now frequently posting dire warnings about the alleged evils of insurance-based healthcare systems. This is exactly that old-school NHS cultism which Streeting used to disavow until five minutes ago. It may work for him. The NHS may be falling apart, but the cult around is still going strong. In the eyes of its keenest defenders, the NHS can do no wrong. They have quietly dropped the old cliché about the NHS being 'the envy of the word', and replaced it with a slightly more subtle version, which goes something like this: Once upon a time, the NHS used to be the best healthcare system in the world. But then, from 2010 on, it was systematically defunded. It was deliberately run into the ground, so that it can be privatised more easily. A privatised system would mean luxury healthcare for the rich, and Wild West medicine for the poor. None of these claims are true. Let's have a look at each of them in turn. 'The NHS used to be the best healthcare system in the world' The NHS was never the best healthcare system in the world. The idea that it ever was can be traced back to a ranking compiled by the Commonwealth Fund, an American healthcare think tank, which relies on a very unusual methodology, in which medical outcomes only account for a fifth of the total score. This matters, because on medical outcomes, the NHS has always been one of the worst-performing healthcare systems in the developed world – as even the Commonwealth Fund study shows. There is no turning point after which the NHS's performance suddenly deteriorated. It was just never good in the first place. '…it was systematically defunded' At the end of the 2010s, age-adjusted real NHS spending per capita was only marginally higher than it had been in the beginning of the decade. Put differently, the NHS budget only just about kept pace with population growth, population ageing, and inflation. This clearly constituted a slowdown in spending increases compared to the previous decade. But it does not constitute a 'defunding'. In any case: that period of relative spending restraint is already over again. The NHS budget was given a massive boost during the pandemic, which has only been partially reversed. Public healthcare spending in the UK stands at just under 9% of GDP: one of the highest levels in the world. '…so that it can be privatised…' Conspiracy theories about secret plans to privatise the NHS have been around for decades. I wrote a report on this three years ago, for which I went through the news archives, and I found warnings about the NHS's imminent demise from every year since 1980. But somehow, it never happens. The NHS remains an unusually state-centred system. Most healthcare systems, including tax-funded ones, use a mix of public, private for-profit and private non-profit providers. 'A privatised system would mean luxury healthcare for the rich, and Wild West medicine for the poor' There are no plans – secret or otherwise – to privatise the NHS. More's the pity. Because there is nothing wrong with private healthcare systems. There are good examples of private, insurance-based healthcare systems, most notably in the Netherlands and Switzerland, which are nothing like the dreaded system of the US. These systems cover everybody: poor people are exempt from health insurance premiums and co-payments. Under these systems, rich and poor alike get faster access to medical treatment, and better medical outcomes, than they would on the NHS. The only thing these people don't get is a naff feel-good mythology around their health systems.
